NASDAQ: NAGE
Healthcare · Biotechnology
Market Cap
$385.99M
52w High
$14.69
52w Low
$4.16
P/E
21.90
Volume
877.47K
Outstanding Shares
80.08M
Price vs Fundamentals
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
The stock fell 43.14% over the last year. Revenue grew 29.95% over the trailing twelve months. Operating margin moved from 7.76% to 11.05%. Free cash flow grew 10.14% over the trailing twelve months.
Visible fundamentals weakened far less than the stock price, and the shares now sit around the 30th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.
This read changes if operating margin (currently 11.05%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging.
Valuation
Stock splits
Every 3 shares became 1
Profitability & growth
Analyst consensus
5
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.06 · Revenue est $30.95M
View